Drug Search Results
More Filters [+]

Etrolizumab

Alternative Names: etrolizumab, rhumab beta7, Etrozulimab, RO5490261, RG7413, RO-5490261, RG-7413
Latest Update: 2024-05-09
Latest Update Note: PubMed Publication

Product Description

Etrolizumab is a next-generation anti-integrin with dual action that targets two pathways of inflammation in the gut. A robust phase 3 clinical program in ulcerative colitis (UC) and Crohn's disease is ongoing and will evaluate the efficacy and safety of etrolizumab in well-defined patient populations in rigorous trials that include direct head-to-head comparisons against approved anti-tumor necrosis factor alpha agents (anti-TNF). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/32445184/)

Mechanisms of Action: ITGA4-B7 Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Etrolizumab

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Croatia, Czech Republic, Estonia, France, Germany, Hungary, Israel, Italy, Korea, Latvia, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Russia, Serbia, Slovakia, South Africa, Spain, Switzerland, Turkey, Ukraine, United Kingdom, United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Colitis, Ulcerative|Crohn Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Lantana

P3

Active, not recruiting

Colitis, Ulcerative

2024-01-23

2017-003649-10

P1

Active, not recruiting

Colitis, Ulcerative|Crohn Disease

2023-03-08

2014-003824-36

P3

Completed

Crohn Disease

2021-09-07

BERGAMOT

P3

Completed

Crohn Disease

2021-09-07

75%

Recent News Events